Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for peripheral vascular disease. Principal products include balloon catheters, vascular grafts, and vessel closure systems. The company operates in a single segment with significant sales in the United States, Europe, and Japan.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $14,598,000 | $13,815,000 |
| Gross Profit | $10,151,000 | $10,318,000 |
| Gross Margin | 69.5% | 74.7% |
| Operating Income (Loss) | $(30,000) | $1,270,000 |
| Net Income | $64,000 | $1,021,000 |
| Cash and Cash Equivalents (End of Period) | $19,103,000 | $23,662,000 |
| Net Cash Used in Operating Activities | $(2,104,000) | $819,000 |
| Total Debt / Long-term Liabilities | $82,000 (Other long-term) | $86,000 (Other long-term) |
Note: The company has no traditional long-term debt but has accrued obligations related to an Italian government loan and acquisition earn-outs.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% year-over-year, driven by higher average selling prices and the acquisition of the LifeSpan Vascular Graft. This was partially offset by a 51% decline in sales of TAArget and UniFit stent grafts following the suspension of clinical trials.
- Margin Compression: Gross margin decreased 5.2% to 69.5%. This decline was attributed to start-up manufacturing costs in Burlington, MA, wind-down costs in Brindisi, Italy, and inventory step-up amortization from the LifeSpan acquisition.
- Operating Expenses: Total operating expenses increased 13% to $10.2 million. This was primarily due to $1.0 million in restructuring charges and $83,000 in impairment charges, which were not present in the prior year quarter.
- Cash Flow: Operating cash flow turned negative ($2.1 million used) compared to positive ($0.8 million provided) in the prior year, driven by a $3.8 million increase in working capital (inventory and receivables) and bonus payments.
Guidance, Outlook, and Risks
- Restructuring: The company is transitioning AlboGraft Vascular Graft production from Italy to Massachusetts. It expects to incur approximately $0.2 million in additional restructuring charges for the remainder of 2011 related to this facility closure. Additionally, $0.7 million in charges are expected in Q2 2011 related to terminating distributor agreements in Spain and Denmark to transition to direct sales.
- Dividends: The Board approved a quarterly cash dividend policy of $0.02 per share. The first dividend was paid in April 2011, and a second was declared in May 2011.
- Stock Repurchase: The company has $1.9 million remaining authority under its $5.0 million stock repurchase program, which expires December 31, 2011.
- Liquidity: Management believes existing cash and cash equivalents ($19.1 million) are sufficient to meet requirements for at least the next twelve months.
- Risks: Key risks include the success of the manufacturing transition, the ability to divest discontinued products (TAArget/UniFit), and foreign currency fluctuations (38% of sales are international).
Investor Verification Checklist
- Restructuring Costs: Verify the actual cash outflow and timing of the $1.0 million restructuring charge, specifically the $0.7 million non-cash deferred rent write-off and the $0.3 million equipment transfer costs.
- Product Mix Shift: Monitor the decline in TAArget/UniFit stent graft sales versus the ramp-up of LifeSpan Vascular Graft sales to ensure the revenue mix stabilizes.
- Working Capital: Review the $3.8 million increase in working capital usage to determine if inventory build-up is sustainable or indicative of slowing demand.
- Italian Loan Obligation: Confirm the settlement of the approximately $0.4 million accelerated loan and grant repayment to the Italian government.
- Direct Sales Transition: Track the financial impact of terminating distributors in Spain and Denmark and the associated $0.9 million and $0.2 million termination payments.